Critical Contrast: Kamada (KMDA) and Catalyst Biosciences (CBIO)
Kamada (NASDAQ: KMDA) and Catalyst Biosciences (NASDAQ:CBIO) are both small-cap medical companies, but which is the better investment? We will contrast the two businesses based on the strength of their dividends, earnings, risk, institutional ownership, profitability, analyst recommendations and valuation.
This table compares Kamada and Catalyst Biosciences’ net margins, return on equity and return on assets.
|Net Margins||Return on Equity||Return on Assets|
This is a summary of current ratings and price targets for Kamada and Catalyst Biosciences, as provided by MarketBeat.
|Sell Ratings||Hold Ratings||Buy Ratings||Strong Buy Ratings||Rating Score|
Kamada presently has a consensus target price of $8.50, suggesting a potential upside of 80.85%. Catalyst Biosciences has a consensus target price of $24.50, suggesting a potential upside of 480.57%. Given Catalyst Biosciences’ higher possible upside, analysts plainly believe Catalyst Biosciences is more favorable than Kamada.
Volatility and Risk
Kamada has a beta of 1.04, suggesting that its stock price is 4% more volatile than the S&P 500. Comparatively, Catalyst Biosciences has a beta of 1.66, suggesting that its stock price is 66% more volatile than the S&P 500.
Insider and Institutional Ownership
7.3% of Kamada shares are held by institutional investors. Comparatively, 29.2% of Catalyst Biosciences shares are held by institutional investors. 5.0% of Catalyst Biosciences shares are held by insiders. Strong institutional ownership is an indication that hedge funds, large money managers and endowments believe a company will outperform the market over the long term.
Earnings & Valuation
This table compares Kamada and Catalyst Biosciences’ gross revenue, earnings per share and valuation.
|Gross Revenue||Price/Sales Ratio||EBITDA||Earnings Per Share||Price/Earnings Ratio|
|Kamada||$87.83 million||1.95||$1.94 million||($0.06)||-78.32|
|Catalyst Biosciences||$561,999.00||32.36||-$19.79 million||($17.78)||-0.24|
Kamada has higher revenue and earnings than Catalyst Biosciences. Kamada is trading at a lower price-to-earnings ratio than Catalyst Biosciences, indicating that it is currently the more affordable of the two stocks.
Kamada Ltd. is an Israel-based biopharmaceutical company, which develops, produces and markets therapeutics, based on chromatographic purification technology. It offers bio-therapeutics for human use, such as specialty proteins, specific immunoglobulins, and other prescription medicines. The Company’s product line includes intravenous AAT for chronic replacement therapy in individuals with congenital alpha-1 antitrypsin deficiency; KamRAB for prophylaxis of rabies infection; KamRho-D IM for prophylaxis of Rh hemolytic disease of the newborn; KamRho-D IV for treatment of immune thrombocytopenic purpura; and IVIG, a replacement therapy in primary and secondary immune therapy. Its product line also comprises Protosol to reduce blood loss in patients undergoing cardiac surgery; Heparin sodium injection for coagulation inhibition and prophylaxis of thromboembolic diseases and Heparin Lock Flush to maintain potency of intravenous injection device among other.
About Catalyst Biosciences
Catalyst Biosciences, Inc., formerly Targacept, Inc., is a clinical-stage biopharmaceutical company. The Company is focused on creating and developing medicines to address serious medical conditions. The Company focuses its product development efforts in the fields of hemostasis, including the treatment of hemophilia and surgical bleeding, and inflammation, including prevention of delayed graft function (DGF) in renal transplants and the treatment of dry age-related macular degeneration (dry AMD), a condition that can cause visual impairment or blindness. The Company’s advanced program is a coagulation Factor VIIa variant, CB 813d, that has completed a Phase I clinical trial in severe hemophilia A and B patients. In addition to its lead Factor VIIa program, it has approximately two other coagulation factors, a Factor IX variant, CB 2679d/ISU 304, that is in advanced preclinical development, and a Factor Xa variant that has reached the advanced lead preclinical-stage of development.
Receive News & Ratings for Kamada Ltd. Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Kamada Ltd. and related companies with MarketBeat.com's FREE daily email newsletter.